Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kimberley Chitko

Nurse Practitioner, Family Winchester, VA Nurse Practitioner

NPI 1164559589 CMS profile 10888479

905 Cedar Creek Grade Ste 200, Winchester, VA 22601

Open in the dashboard

General payments

$13,521

685 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberley Chitko of Winchester, VA is reported in the CMS Open Payments database as having received $13,521 across 685 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,679 179
2024 General $3,853 185
2023 General $3,792 213
2022 General $2,197 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberley Chitko
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kimberley Chitko were reported at $3,679. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kimberley Chitko Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $2,197 $141 $44–$430 $149
2023 $3,792 $154 $49–$476 $160
2024 $3,853 $165 $51–$504 $164
2025 $3,679 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Biogen, Inc. $1,822 77 payments
  2. EMD Serono, Inc. $1,426 37 payments
  3. Alexion Pharmaceuticals, Inc. $1,145 44 payments
  4. AbbVie, Inc. $1,090 85 payments
  5. Lilly USA, LLC $913 51 payments
  6. Pfizer Inc. $746 77 payments
  7. Teva Pharmaceuticals USA, Inc. $689 36 payments
  8. Lundbeck LLC $624 31 payments
  9. TG Therapeutics, Inc. $436 20 payments
  10. Amneal Pharmaceuticals LLC $395 18 payments
  11. Other $4,236 209 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $13,033 679 payments
  2. Consulting Fee $300 2 payments
  3. Education $189 4 payments
Products named General payments · program years 2022–2025
  1. TYSABRI $1,468 64 payments
  2. ULTOMIRIS $902 37 payments
  3. NURTEC ODT $699 72 payments
  4. VUMERITY Neurology $699 33 payments
  5. Leqembi $462 24 payments
  6. VUMERITY Neurology $445 14 payments
  7. Austedo XR $444 26 payments
  8. BRIUMVI $436 20 payments
  9. ZAVZPRET $435 44 payments
  10. VYEPTI $428 21 payments
  11. Other $8,095 445 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,883

Median for Nurse Practitioner: 389

Drug cost

$244,238

Median for Nurse Practitioner: $21,885

Branded share of claims

32.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Teriflunomide Generic 12 $54,212
Nurtec Odt Rimegepant Sulfate Brand 31 $50,291
Aptiom Eslicarbazepine Acetate Brand 29 $34,846
Aimovig Autoinjector Erenumab-Aooe Brand 17 $23,109
Emgality Pen Galcanezumab-Gnlm Brand 15 $19,309
Ubrelvy Ubrogepant Brand 18 $18,942
Ajovy Autoinjector Fremanezumab-Vfrm Brand 15 $11,097
Levetiracetam Er Levetiracetam Brand 67 $4,012
Modafinil Generic 44 $3,402
Propranolol Hcl Er Propranolol Hcl Brand 74 $2,685

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
$297 — —
WAKIX
$242 — —
Leqembi
$220 — —
BRIUMVI
$198 — —
Austedo XR
$198 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

685 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record